BOOK
New Trends in the Treatment of Sarcoma, An issue of Surgical Clinics of North America, E-Book
Jeffrey M. Farma | Andrea S. Porpiglia
(2016)
Additional Information
Book Details
Abstract
This issue of Surgical Clinics of North America, guest edited by Drs. Jeffrey M. Farma and Andrea Porpiglia, is devoted to Sarcoma. They have assembled expert authors to review the following topics: Epidemiology and Etiology of Sarcomas; Management of Extremity Sarcomas; Management of Retroperitoneal Sarcomas; Management of Dermatofibrosarcoma Protuberans; Management of Desmoids; Management of Truncal Sarcomas; Management of Bone Sarcomas; Management of Pediatric Sarcomas; Local Recurrence of Sarcomas; Management of Metastatic Disease; Imaging of Sarcomas; Management of Gastrointestinal Stromal Tumors; Management of Breast Sarcoma; Chemotherapy for Sarcomas; Pathology and Classification of Sarcomas; Radiation Therapy for Sarcomas; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| New Trends in theTreatment of Sarcoma | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword\r | vii | ||
| Preface: Current Treatment of Sarcomas\r | vii | ||
| Epidemiology and Etiology of Sarcomas\r | vii | ||
| Bone and Soft Tissue Pathology: Diagnostic and Prognostic Implications\r | vii | ||
| Radiologic Approach to Bone and Soft Tissue Sarcomas\r | vii | ||
| Multimodality Management of Soft Tissue Tumors in the Extremity\r | viii | ||
| Retroperitoneal Sarcomas\r | viii | ||
| Management of Truncal Sarcoma\r | viii | ||
| Management of Desmoids\r | viii | ||
| Dermatofibrosarcoma Protuberans\r | ix | ||
| Management of Breast Sarcoma\r | ix | ||
| Management of Gastrointestinal Stromal Tumors\r | ix | ||
| Management of Bone Sarcoma\r | ix | ||
| Pediatric Sarcomas\r | x | ||
| The Role for Radiation Therapy in the Management of Sarcoma\r | x | ||
| Systemic Therapy for Advanced Soft Tissue Sarcoma\r | x | ||
| Local Recurrence of Extremity Soft Tissue Sarcoma\r | x | ||
| Surgical Management of Metastatic Disease\r | xi | ||
| SURGICAL CLINICS\rOF NORTH AMERICA | xii | ||
| FORTHCOMING ISSUES | xii | ||
| December 2016 | xii | ||
| February 2017 | xii | ||
| April 2017 | xii | ||
| RECENT ISSUES | xii | ||
| August 2016 | xii | ||
| June 2016 | xii | ||
| April 2016 | xii | ||
| February 2016 | xii | ||
| Foreword:\rSarcoma | xiii | ||
| Preface:\rCurrent Treatment of Sarcomas | xv | ||
| Epidemiology and Etiology of Sarcomas | 901 | ||
| Key points | 901 | ||
| INTRODUCTION | 901 | ||
| EPIDEMIOLOGY | 901 | ||
| Soft Tissue Sarcoma | 902 | ||
| Bone Sarcoma | 902 | ||
| Cutaneous Sarcoma | 903 | ||
| Pediatric Sarcoma | 903 | ||
| ETIOLOGY | 903 | ||
| Genetic Susceptibility | 903 | ||
| Li-Fraumeni syndrome | 904 | ||
| Retinoblastoma | 905 | ||
| Neurofibromatosis type 1 | 906 | ||
| Familial adenomatous polyposis | 907 | ||
| Gastrointestinal stromal tumors | 907 | ||
| Bloom’s syndrome, Werner’s syndrome, and Rothmund-Thomson syndrome | 907 | ||
| Ionizing Radiation | 908 | ||
| Prior breast cancer | 909 | ||
| Other Environmental Factors | 909 | ||
| SUMMARY | 910 | ||
| REFERENCES | 910 | ||
| Bone and Soft Tissue Pathology | 915 | ||
| Key points | 915 | ||
| INTRODUCTION | 915 | ||
| WORLD HEALTH ORGANIZATION 2013 UPDATE | 916 | ||
| PATHOLOGIC GRADING OF SOFT TISSUE SARCOMAS | 917 | ||
| PATHOLOGICAL STAGING OF SOFT TISSUE SARCOMAS | 918 | ||
| PATHOLOGIC GRADING OF BONE TUMORS | 918 | ||
| PATHOLOGIC STAGING OF BONE TUMORS | 920 | ||
| OVERVIEW OF THE PATHOLOGIC ASPECT OF DIAGNOSIS, PROGNOSIS, AND THERANOSTICS | 921 | ||
| MALIGNANT SOFT TISSUE AND BONE TUMORS | 922 | ||
| Liposarcoma | 922 | ||
| Ancillary studies | 922 | ||
| Prognostic implications | 923 | ||
| Fibrosarcoma | 923 | ||
| Histopathology and ancillary studies | 924 | ||
| Prognostic implications | 924 | ||
| Undifferentiated Sarcomas | 925 | ||
| Ancillary studies | 925 | ||
| Prognostic implications | 925 | ||
| Angiosarcoma | 926 | ||
| Radiologic Approach to Bone and Soft Tissue Sarcomas | 963 | ||
| Key points | 963 | ||
| IMAGING MODALITIES | 964 | ||
| EVALUATION OF A NEWLY SUSPECTED MUSCULOSKELETAL TUMOR | 964 | ||
| Step 1: Determination of Risk of Malignancy | 966 | ||
| Bone lesions | 967 | ||
| Soft tissue masses | 967 | ||
| Step 2: Assessment of Tumor Composition to Predict a Specific Histopathologic Diagnosis | 969 | ||
| TUMOR STAGING, RESPONSE TO NEOADJUVANT THERAPY, AND POSTOPERATIVE SURVEILLANCE | 973 | ||
| REFERENCES | 974 | ||
| Multimodality Management of Soft Tissue Tumors in the Extremity | 977 | ||
| Key points | 977 | ||
| INTRODUCTION | 977 | ||
| CLINICAL PRESENTATION AND DIAGNOSIS | 978 | ||
| IMAGING THE PRIMARY TUMOR | 978 | ||
| BIOPSY TECHNIQUES | 980 | ||
| STAGING AND EXTENT OF DISEASE WORK-UP | 981 | ||
| SURGICAL APPROACH | 982 | ||
| CLINICAL OUTCOMES | 984 | ||
| MULTIMODALITY TREATMENT | 984 | ||
| Adjuvant and Neoadjuvant Radiation | 985 | ||
| Adjuvant and Neoadjuvant Chemotherapy | 986 | ||
| ISOLATED LIMB PERFUSION | 988 | ||
| FOLLOW-UP | 988 | ||
| SUMMARY | 989 | ||
| ACKNOWLEDGMENTS | 989 | ||
| REFERENCES | 989 | ||
| Retroperitoneal Sarcomas | 993 | ||
| Key points | 993 | ||
| INTRODUCTION | 993 | ||
| SURGERY | 994 | ||
| RADIATION THERAPY | 996 | ||
| Preoperative Radiation Therapy | 996 | ||
| Postoperative Radiation Therapy | 996 | ||
| Intraoperative Radiation Therapy | 997 | ||
| CHEMOTHERAPY | 998 | ||
| RECURRENCE | 998 | ||
| SURVEILLANCE | 998 | ||
| SUMMARY | 998 | ||
| REFERENCES | 999 | ||
| Management of Truncal Sarcoma | 1003 | ||
| Key points | 1003 | ||
| INTRODUCTION | 1003 | ||
| General Principles | 1004 | ||
| UNIQUE CONSIDERATIONS FOR TRUNCAL SARCOMA | 1005 | ||
| Desmoid Tumors | 1005 | ||
| Soft Tissue Sarcoma of the Inguinal Region | 1007 | ||
| Lymph Node Biopsy | 1009 | ||
| Chest Wall Sarcoma | 1009 | ||
| Radiation-Associated Sarcoma | 1010 | ||
| Surveillance of Truncal Sarcoma | 1010 | ||
| SUMMARY | 1011 | ||
| REFERENCES | 1011 | ||
| Management of Desmoids | 1015 | ||
| Key points | 1015 | ||
| INTRODUCTION | 1015 | ||
| Pathogenesis | 1016 | ||
| Presentation | 1016 | ||
| EVALUATION | 1018 | ||
| Radiologic Evaluation | 1018 | ||
| Diagnosis | 1018 | ||
| TREATMENT | 1018 | ||
| Surgery | 1019 | ||
| Systemic Therapy | 1021 | ||
| Hormonal and nonsteroidal antiinflammatory drugs | 1021 | ||
| Chemotherapy | 1021 | ||
| Targeted therapy | 1022 | ||
| Novel therapies | 1023 | ||
| Radiation Therapy | 1023 | ||
| Watchful Waiting | 1024 | ||
| SURVEILLANCE | 1026 | ||
| SUMMARY | 1026 | ||
| REFERENCES | 1026 | ||
| Dermatofibrosarcoma Protuberans | 1031 | ||
| Key points | 1031 | ||
| INTRODUCTION | 1031 | ||
| EPIDEMIOLOGY AND SUBTYPES | 1032 | ||
| GENETICS | 1033 | ||
| RISK FACTORS | 1033 | ||
| DIAGNOSIS AND EVALUATION | 1034 | ||
| PATHOLOGIC EVALUATION | 1035 | ||
| TREATMENT | 1037 | ||
| Surgery for Primary Tumors | 1037 | ||
| Reconstruction of Dermatofibrosarcoma Protuberans Surgical Defects | 1039 | ||
| Surgery for Recurrent Tumors | 1039 | ||
| Radiotherapy | 1039 | ||
| Systemic Therapy | 1040 | ||
| METASTATIC DISEASE | 1041 | ||
| FOLLOW-UP AND SURVEILLANCE | 1041 | ||
| SUMMARY | 1041 | ||
| REFERENCES | 1042 | ||
| Management of Breast Sarcoma | 1047 | ||
| Key points | 1047 | ||
| CLINICAL PRESENTATION AND INITIAL EVALUATION | 1048 | ||
| MULTIDISCIPLINARY MANAGEMENT | 1049 | ||
| SURGICAL MANAGEMENT | 1049 | ||
| RADIATION THERAPY | 1051 | ||
| CHEMOTHERAPY | 1053 | ||
| CLINICAL OUTCOMES AND PROGNOSTIC FACTORS | 1054 | ||
| SUMMARY | 1055 | ||
| REFERENCES | 1055 | ||
| Management of Gastrointestinal Stromal Tumors | 1059 | ||
| Key points | 1059 | ||
| INTRODUCTION | 1059 | ||
| MOLECULAR PATHOLOGIC CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMOR | 1060 | ||
| PATHOLOGIC CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMOR | 1060 | ||
| Immunohistochemistry | 1060 | ||
| Molecular Pathologic Features | 1061 | ||
| Micro–Gastrointestinal Stromal Tumor | 1061 | ||
| MANAGEMENT OF PRIMARY GASTROINTESTINAL STROMAL TUMOR | 1062 | ||
| Clinical Presentation | 1062 | ||
| Surgery | 1062 | ||
| Neoadjuvant Therapy | 1064 | ||
| Adjuvant Therapy | 1064 | ||
| Assessment of Risk for Recurrence | 1064 | ||
| MANAGEMENT OF RECURRENT OR METASTATIC GASTROINTESTINAL STROMAL TUMOR | 1066 | ||
| Systemic Therapy | 1066 | ||
| Therapy Beyond Imatinib | 1067 | ||
| Surgical Metastasectomy | 1069 | ||
| Focal Modalities for Management of Metastatic Disease | 1070 | ||
| SUMMARY | 1070 | ||
| REFERENCES | 1070 | ||
| Management of Bone Sarcoma | 1077 | ||
| Key points | 1077 | ||
| INTRODUCTION | 1077 | ||
| Incidence and Epidemiology | 1077 | ||
| Pretreatment Evaluation and Staging | 1078 | ||
| Biopsy | 1078 | ||
| Percutaneous needle biopsy | 1080 | ||
| Treatment Overview | 1081 | ||
| TREATMENT MODALITIES | 1082 | ||
| Chemotherapy | 1082 | ||
| Chemotherapy for osteosarcoma | 1083 | ||
| Chemotherapy for Ewing sarcoma | 1084 | ||
| Chemotherapy for chondrosarcoma | 1085 | ||
| Radiation Therapy | 1085 | ||
| Surgical Resection | 1087 | ||
| Resection: amputation versus limb salvage | 1087 | ||
| Local recurrence | 1088 | ||
| RECONSTRUCTIVE CONSIDERATIONS | 1089 | ||
| Allograft Reconstruction | 1090 | ||
| Allograft-Prosthetic Composites | 1090 | ||
| Endoprosthetic Reconstruction | 1091 | ||
| Extracorporeal-Irradiated Autografts | 1092 | ||
| Emerging Surgical and Implant Technology | 1093 | ||
| Computer-Aided Surgery | 1093 | ||
| SUMMARY | 1095 | ||
| REFERENCES | 1095 | ||
| Pediatric Sarcomas | 1107 | ||
| Key points | 1107 | ||
| RHABDOMYOSARCOMA | 1107 | ||
| Epidemiology | 1107 | ||
| Prognosis | 1108 | ||
| Classification | 1109 | ||
| Staging and Risk Stratification | 1110 | ||
| Treatment | 1110 | ||
| Summary | 1112 | ||
| NONRHABDOMYOSARCOMA SOFT TISSUE SARCOMAS | 1112 | ||
| Epidemiology | 1112 | ||
| Histology | 1112 | ||
| Prognostic Factors | 1113 | ||
| Staging | 1114 | ||
| Treatment | 1114 | ||
| Low risk | 1114 | ||
| Intermediate risk | 1115 | ||
| High risk | 1115 | ||
| Summary | 1115 | ||
| BONE SARCOMAS | 1115 | ||
| Osteosarcoma | 1115 | ||
| Epidemiology | 1115 | ||
| Clinical presentation | 1116 | ||
| Prognostic factors | 1116 | ||
| Tumor location | 1116 | ||
| Tumor size | 1116 | ||
| Localized versus metastatic disease at diagnosis | 1117 | ||
| Surgical resectability | 1117 | ||
| Degree of tumor necrosis after neoadjuvant chemotherapy | 1117 | ||
| Staging | 1117 | ||
| Treatment | 1117 | ||
| Ewing Sarcoma | 1118 | ||
| Epidemiology | 1118 | ||
| Clinical presentation | 1118 | ||
| Prognostic factors | 1118 | ||
| Localized versus metastatic disease | 1119 | ||
| Degree of response to neoadjuvant chemotherapy | 1119 | ||
| Tumor location | 1119 | ||
| Tumor size | 1119 | ||
| Age | 1119 | ||
| Gender | 1119 | ||
| Lactate dehydrogenase | 1119 | ||
| Staging | 1119 | ||
| Treatment | 1119 | ||
| SUMMARY | 1120 | ||
| REFERENCES | 1120 | ||
| The Role for Radiation Therapy in the Management of Sarcoma | 1127 | ||
| Key points | 1127 | ||
| INTRODUCTION | 1127 | ||
| AMPUTATION VERSUS LIMB-SPARING SURGERY WITH ADJUVANT RADIATION | 1127 | ||
| LIMB-SPARING SURGERY WITH OR WITHOUT ADJUVANT RADIATION | 1128 | ||
| PREOPERATIVE VERSUS POSTOPERATIVE RADIOTHERAPY | 1130 | ||
| IMAGE GUIDANCE AND INTENSITY-MODULATED RADIOTHERAPY | 1132 | ||
| POSITIVE MARGIN AFTER NEOADJUVANT RADIATION AND SURGICAL RESECTION | 1133 | ||
| UNPLANNED EXCISION | 1133 | ||
| RADIATION TREATMENT PLANNING | 1133 | ||
| RADIATION TOXICITY | 1134 | ||
| Acute | 1134 | ||
| Late | 1134 | ||
| RADIATION-ASSOCIATED SARCOMA | 1135 | ||
| RETROPERITONEAL SARCOMA | 1135 | ||
| SUMMARY | 1136 | ||
| REFERENCES | 1136 | ||
| Systemic Therapy for Advanced Soft Tissue Sarcoma | 1141 | ||
| Key points | 1141 | ||
| BACKGROUND | 1141 | ||
| DOXORUBICIN | 1142 | ||
| IFOSFAMIDE | 1142 | ||
| GEMCITABINE | 1146 | ||
| DACARBAZINE AND TEMOZOLOMIDE | 1147 | ||
| PACLITAXEL | 1148 | ||
| PAZOPANIB | 1148 | ||
| TRABECTEDIN | 1149 | ||
| NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED SOFT TISSUE SARCOMA | 1150 | ||
| INVESTIGATIONAL AGENTS | 1151 | ||
| Eribulin | 1151 | ||
| Aldoxorubicin | 1151 | ||
| Olaratumab | 1151 | ||
| Palbociclib | 1152 | ||
| SUMMARY | 1152 | ||
| REFERENCES | 1152 | ||
| Local Recurrence of Extremity Soft Tissue Sarcoma | 1157 | ||
| Key points | 1157 | ||
| INTRODUCTION | 1157 | ||
| MANAGEMENT OF RECURRENCE | 1159 | ||
| Surgical Resection and Irradiation of Sarcoma Recurrence | 1159 | ||
| Amputation for Sarcoma Recurrence | 1161 | ||
| Chemotherapy for Sarcoma Recurrence | 1162 | ||
| Regional Lymphadenectomy for Sarcoma Recurrence | 1163 | ||
| Regional Therapy for Sarcoma Recurrence | 1163 | ||
| OVERALL SURVIVAL AFTER LOCAL RECURRENCE | 1168 | ||
| SUMMARY | 1169 | ||
| REFERENCES | 1169 | ||
| Surgical Management of Metastatic Disease | 1175 | ||
| Key points | 1175 | ||
| INTRODUCTION | 1175 | ||
| DIAGNOSIS AND PATTERN OF METASTATIC SOFT TISSUE SARCOMA | 1176 | ||
| THE ROLE OF METASTASECTOMY FOR SARCOMA | 1176 | ||
| Patient Selection for Metastasectomy | 1177 | ||
| Pulmonary Metastasectomy for Sarcoma | 1177 | ||
| Outcomes following pulmonary metastasectomy for soft tissue sarcoma | 1180 | ||
| Outcomes following pulmonary metastasectomy for bone sarcoma | 1181 | ||
| Approach to recurrent metastases | 1182 | ||
| Patients presenting with synchronous metastases | 1182 | ||
| Hepatic Resection for Metastatic Sarcoma | 1183 | ||
| Outcomes following hepatic resection for metastatic soft tissue sarcoma | 1183 | ||
| Outcomes following hepatic resection for metastatic leiomyosarcoma | 1185 | ||
| OTHER TREATMENT MODALITIES FOR METASTATIC SARCOMA | 1186 | ||
| Chemotherapy | 1186 | ||
| Radiation Therapy | 1187 | ||
| Ablative Techniques | 1188 | ||
| Liver ablation | 1188 | ||
| Lung ablation | 1188 | ||
| SUMMARY | 1188 | ||
| REFERENCES | 1189 | ||
| Index | 1193 |